Volume 9, Number 7—July 2003
Research
Antimicrobial Susceptibility Breakpoints and First-Step parC Mutations in Streptococcus pneumoniae: Redefining Fluoroquinolone Resistance
Sue Lim*†, Darrin Bast*†, Allison McGeer*†, Joyce de Azavedo*†, and Donald E. Low*†
Table 2
Number of isolates with ParC and GyrA amino acid substitutions and their corresponding levofloxacin MICs
| MIC (μg/mL) | No. strains with amino acid substitutions in | |
|---|---|---|
| ParC (%) | ParC and GyrA (%) | |
| 2 | 48/82 (59) | 0/29a (0) |
| 4 | 5/8 (63) | 3/8 (38) |
| 8 | 0/10 (0) | 10/10 (100) |
| ≥16 | 0/15 (0) | 15/15 (100) |
a29/82 isolates were randomly examined for GyrA mutations.
Page created: December 22, 2010
Page updated: December 22, 2010
Page reviewed: December 22, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.